Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. (4th May 2019)

• Record Type: Journal Article
• Authors: Varu, Abhishek; Wilson, Florence R.; Dyrda, Peter; Hazel, Maureen; Hutton, Brian; Cameron, Chris
• Is Part Of: Current medical research and opinion. Volume 35:Number 5(2019)
• Page Start: 733
• Page End: 756
• Publication Date: 2019-05-04
• Subjects: Network meta-analysis -- Crohn's disease -- biologics -- adaptive trial design -- study design -- indirect treatment comparisons -- ustekinumab; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2019.1580094
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: Several biologic therapies are available for the treatment of mild-to-moderate Crohn's disease (CD). This network meta-analysis (NMA) aimed to assess the comparative efficacy of ustekinumab, adalimumab, vedolizumab and infliximab in the maintenance of clinical response and remission after 1 year of treatment. Methods: A systematic literature search was performed to identify relevant randomized controlled trials (RCTs). Key outcomes of interest were clinical response (CD activity index [CDAI] reduction of 100 points; CDAI-100) and remission (CDAI score under 150 points; CDAI < 150). A treatment sequence Bayesian NMA was conducted to account for the re-randomization of patients based on different clinical definitions, the lack of similarity of the common comparator for each trial and the full treatment pathway from the induction phase onwards. Results: Thirteen RCTs were identified. Ustekinumab 90 mg q8w was associated with statistically significant improvement in clinical response relative to placebo and vedolizumab 300 mg. For clinical remission, ustekinumab 90 mg q8w was associated with statistically significant improvement relative to placebo and vedolizumab 300 mg q8w. Findings from sub-population analyses had similar results but were not statistically significant. Conclusions: The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1 year compared with placebo, adalimumab and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence.